The Middle East and Africa non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 6.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030. Market Segmentation: Middle East and Africa Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2030 Some of the major factors contributing to the growth of Middle East and Africa non-Hodgkin lymphoma diagnostics market are: • Increased growth in the prevalence of non-Hodgkin lymphoma • Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma Market Players: Some of the major players operating in the Middle East and Africa non-Hodgkin lymphoma diagnostics market are: • CANON MEDICAL SYSTEMS CORPORATION • Koninklijke Philips N.V. • Siemens Healthcare GmbH • Danaher. • Bio-Rad Laboratories, Inc. • General Electric Company • Sysmex Corporation • Grail • F. Hoffmann-La Roche • Neusoft Corporation • Agilent Technologies, Inc. • NeoGenomics Laboratories • Hologic, Inc • Integrated DNA Technologies, Inc. • CENTOGENE N.V. • Merit Medical Systems • Invitae Corporation • PerkinElmer Inc. • QIAGEN • GeneDx, LLC

1 INTRODUCTION 83 1.1 OBJECTIVES OF THE STUDY 83 1.2 MARKET DEFINITION 83 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 83 1.4 LIMITATIONS 85 1.5 MARKETS COVERED 86 2 MARKET SEGMENTATION 89 2.1 MARKETS COVERED 89 2.2 GEOGRAPHICAL SCOPE 90 2.3 YEARS CONSIDERED FOR THE STUDY 91 2.4 CURRENCY AND PRICING 91 2.5 DBMR TRIPOD DATA VALIDATION MODEL 92 2.6 MULTIVARIATE MODELLING 95 2.7 PRODUCT TYPE LIFELINE CURVE 95 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96 2.9 DBMR MARKET POSITION GRID 97 2.10 MARKET APPLICATION COVERAGE GRID 98 2.11 VENDOR SHARE ANALYSIS 99 2.12 SECONDARY SOURCES 100 2.13 ASSUMPTIONS 100 3 EXECUTIVE SUMMARY 101 4 PREMIUM INSIGHTS 104 4.1 PESTEL ANALYSIS 105 4.2 PORTER'S 5 FORCES 106 5 INDUSTRY INSIGHTS 107 6 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 108 7 MARKET OVERVIEW 110 7.1 DRIVERS 112 7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 112 7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 112 7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 112 7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 113 7.2 RESTRAINTS 113 7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 113 7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 114 7.3 OPPORTUNITIES 115 7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 115 7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 115 7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 115 7.4 CHALLENGES 116 7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 116 7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 116 7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 117 8 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 118 8.1 OVERVIEW 119 8.2 IMAGING 122 8.2.1 COMPUTED TOMOGRAPHY (CT) 123 8.2.2 CHEST X-RAY 123 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 123 8.2.4 ULTRASOUND 123 8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 123 8.3 BIOPSY 123 8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 124 8.3.2 CORE NEEDLE BIOPSY 124 8.4 IMMUNOHISTOCHEMISTRY 124 8.5 BIOMARKER TEST 125 8.5.1 BETA 2-M 126 8.5.2 LDH 126 8.5.3 CA-125 126 8.5.4 TP53 126 8.5.5 NPM1 127 8.5.6 OTHERS 127 8.6 GENETIC TEST 127 8.7 CYTOGENETICS 127 8.8 LUMBAR PUNCTURE (SPINAL TAP) 128 8.9 BLOOD TEST 129 8.10 CYTOCHEMISTRY 129 8.11 OTHERS 130 9 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 131 9.1 OVERVIEW 132 9.2 AGGRESSIVE LYMPHOMAS 134 9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 135 9.2.1.1 INSTRUMENT BASED PRODUCTS 136 9.2.1.2 PLATFORM BASED PRODUCTS 136 9.2.1.3 KITS AND REAGENTS 136 9.2.1.4 OTHER CONSUMABLES 136 9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 136 9.2.2.1 INSTRUMENT BASED PRODUCTS 137 9.2.2.2 PLATFORM BASED PRODUCTS 137 9.2.2.3 KITS AND REAGENTS 137 9.2.2.4 OTHER CONSUMABLES 137 9.2.3 MANTLE CELL LYMPHOMA 137 9.2.3.1 INSTRUMENT BASED PRODUCTS 138 9.2.3.2 PLATFORM BASED PRODUCTS 138 9.2.3.3 KITS AND REAGENTS 138 9.2.3.4 OTHER CONSUMABLES 138 9.2.4 PERIPHERAL T-CELL LYMPHOMA 138 9.2.4.1 INSTRUMENT BASED PRODUCTS 139 9.2.4.2 PLATFORM BASED PRODUCTS 139 9.2.4.3 KITS AND REAGENTS 139 9.2.4.4 OTHER CONSUMABLES 139 9.2.5 LYMPHOBLASTIC LYMPHOMA 139 9.2.5.1 INSTRUMENT BASED PRODUCTS 140 9.2.5.2 PLATFORM BASED PRODUCTS 140 9.2.5.3 KITS AND REAGENTS 140 9.2.5.4 OTHER CONSUMABLES 140 9.2.6 BURKITT LYMPHOMA 140 9.2.6.1 INSTRUMENT BASED PRODUCTS 141 9.2.6.2 PLATFORM BASED PRODUCTS 141 9.2.6.3 KITS AND REAGENTS 141 9.2.6.4 OTHER CONSUMABLES 141 9.3 INDOLENT LYMPHOMAS 141 9.3.1 FOLLICULAR LYMPHOMA 142 9.3.1.1 INSTRUMENT BASED PRODUCTS 143 9.3.1.2 PLATFORM BASED PRODUCTS 143 9.3.1.3 KITS AND REAGENTS 143 9.3.1.4 OTHER CONSUMABLES 143 9.3.2 CUTANEOUS T-CELL LYMPHOMA 143 9.3.2.1 INSTRUMENT BASED PRODUCTS 144 9.3.2.2 PLATFORM BASED PRODUCTS 144 9.3.2.3 KITS AND REAGENTS 144 9.3.2.4 OTHER CONSUMABLES 144 9.3.3 MARGINAL ZONE B CELL LYMPHOMA 144 9.3.3.1 INSTRUMENT BASED PRODUCTS 145 9.3.3.2 PLATFORM BASED PRODUCTS 145 9.3.3.3 KITS AND REAGENTS 145 9.3.3.4 OTHER CONSUMABLES 145 9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 145 9.3.4.1 INSTRUMENT BASED PRODUCTS 146 9.3.4.2 PLATFORM BASED PRODUCTS 146 9.3.4.3 KITS AND REAGENTS 146 9.3.4.4 OTHER CONSUMABLES 146 9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 146 9.3.5.1 INSTRUMENT BASED PRODUCTS 147 9.3.5.2 PLATFORM BASED PRODUCTS 147 9.3.5.3 KITS AND REAGENTS 147 9.3.5.4 OTHER CONSUMABLES 147 10 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 148 10.1 OVERVIEW 149 10.2 SCREENING 151 10.2.1 INSTRUMENT BASED PRODUCTS 152 10.2.2 PLATFORM BASED PRODUCTS 152 10.2.3 KITS AND REAGENTS 153 10.2.4 OTHER CONSUMABLES 153 10.3 DIAGNOSTIC AND PREDICTIVE 153 10.3.1 INSTRUMENT BASED PRODUCTS 154 10.3.2 PLATFORM BASED PRODUCTS 154 10.3.3 KITS AND REAGENTS 154 10.3.4 OTHER CONSUMABLES 154 10.4 PROGNOSTIC 154 10.4.1 INSTRUMENT BASED PRODUCTS 155 10.4.2 PLATFORM BASED PRODUCTS 155 10.4.3 KITS AND REAGENTS 155 10.4.4 OTHER CONSUMABLES 156 10.5 RESEARCH 156 10.5.1 INSTRUMENT BASED PRODUCTS 157 10.5.2 PLATFORM BASED PRODUCTS 157 10.5.3 KITS AND REAGENTS 157 10.5.4 OTHER CONSUMABLES 157 11 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 158 11.1 OVERVIEW 159 11.2 STAGE IV 161 11.3 STAGE I 162 11.4 STAGE III 163 11.5 STAGE II 164 11.6 STAGE 0 165 12 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 166 12.1 OVERVIEW 167 12.2 FLUORESCENT IN SITU HYBRIDIZATION 169 12.3 NEXT GENERATION SEQUENCING 170 12.4 FLUORIMMUNOASSAY 171 12.5 COMPARATIVE GENOMIC HYBRIDIZATION 172 12.6 IMMUNOHISTOLOCHEMICAL 172 12.7 OTHER 173 13 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 174 13.1 OVERVIEW 175 13.2 INSTRUMENT BASED PRODUCTS 177 13.2.1 IMAGING 178 13.2.2 BIOPSY 178 13.3 PLATFORM BASED PRODUCTS 179 13.3.1 NEXT-GENERATION SEQUENCING 180 13.3.2 MICROARRAYS 180 13.3.3 PCR 180 13.3.4 OTHERS 180 13.4 KITS AND REAGENTS 180 13.4.1 NON-HODGKIN LYMPHOMA PANELS 181 13.4.2 IMMUNOHISTOCHEMISTRY STAINS 181 13.4.3 OTHERS 181 13.5 OTHER CONSUMABLES 182 14 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 183 14.1 OVERVIEW 184 14.2 HOSPITALS 186 14.3 DIAGNOSTIC CENTERS 187 14.4 CANCER RESEARCH CENTERS 188 14.5 ACADEMIC INSTITUTES 189 14.6 AMBULATORY SURGICAL CENTERS 189 14.7 OTHERS 190 15 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 191 15.1 OVERVIEW 192 15.2 DIRECT TENDER 194 15.3 RETAIL SALES 195 15.4 OTHERS 196 16 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 197 16.1 MIDDLE EAST AND AFRICA 198 16.1.1 SOUTH AFRICA 216 16.1.2 SAUDI ARABIA 229 16.1.3 U.A.E 242 16.1.4 EGYPT 255 16.1.5 ISRAEL 269 16.1.6 REST OF MIDDLE EAST AND AFRICA 283 17 MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 284 17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 284 18 SWOT ANALYSIS 285 19 MIDDLE EAST & AFRICA NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 286 19.1 CANON MEDICAL SYSTEMS CORPORATION 286 19.1.1 COMPANY SNAPSHOT 286 19.1.2 REVENUE ANALYSIS 286 19.1.3 COMPANY SHARE ANALYSIS 287 19.1.4 PRODUCT PORTFOLIO 287 19.1.5 RECENT DEVELOPMENT 287 19.2 KONINKLIJKE PHILIPS N.V 288 19.2.1 COMPANY SNAPSHOT 288 19.2.2 REVENUE ANALYSIS 288 19.2.3 COMPANY SHARE ANALYSIS 289 19.2.4 PRODUCT PORTFOLIO 289 19.2.5 RECENT DEVELOPMENTS 289 19.3 SIEMENS HEALTHCARE GMBH 290 19.3.1 COMPANY SNAPSHOT 290 19.3.2 REVENUE ANALYSIS 290 19.3.3 COMPANY SHARE ANALYSIS 291 19.3.4 PRODUCT PORTFOLIO 291 19.3.5 RECENT DEVELOPMENT 292 19.4 DANAHER 293 19.4.1 COMPANY SNAPSHOT 293 19.4.2 REVENUE ANALYSIS 293 19.4.3 COMPANY SHARE ANALYSIS 294 19.4.4 PRODUCT PORTFOLIO 294 19.4.5 RECENT DEVELOPMENTS 295 19.5 BIO-RAD LABORATORIES, INC 296 19.5.1 COMPANY SNAPSHOT 296 19.5.2 REVENUE ANALYSIS 296 19.5.3 COMPANY SHARE ANALYSIS 297 19.5.4 PRODUCT PORTFOLIO 297 19.5.5 RECENT DEVELOPMENT 297 19.6 AGILENT TECHNOLOGIES, INC 298 19.6.1 COMPANY PROFILE 298 19.6.2 REVENUE ANALYSIS 298 19.6.3 PRODUCT PORTFOLIO 299 19.6.4 RECENT DEVELOPMENT 299 19.7 CENTOGENE N.V 300 19.7.1 COMPANY SNAPSHOT 300 19.7.2 PRODUCT PORTFOLIO 300 19.7.3 RECENT DEVELOPMENT 300 19.8 F. HOFFMANN- LA ROCHE LTD 301 19.8.1 COMPANY SNAPSHOT 301 19.8.2 REVENUE ANALYSIS 301 19.8.3 PRODUCT PORTFOLIO 302 19.8.4 RECENT DEVELOPMENTS 302 19.9 GENERAL ELECTRIC COMPANY 303 19.9.1 COMPANY SNAPSHOT 303 19.9.2 REVENUE ANALYSIS 303 19.9.3 PRODUCT PORTFOLIO 304 19.9.4 RECENT DEVELOPMENTS 304 19.10 GENEDX, LLC 305 19.10.1 COMPANY SNAPSHOT 305 19.10.2 PRODUCT PORTFOLIO 305 19.10.3 RECENT DEVELOPMENT 305 19.11 GRAIL 306 19.11.1 COMPANY PROFILE 306 19.11.2 PRODUCT PORTFOLIO 306 19.11.3 RECENT DEVELOPMENT 306 19.12 HOLOGIC INC 307 19.12.1 COMPANY SNAPSHOT 307 19.12.2 REVENUE ANALYSIS 307 19.12.3 PRODUCT PORTFOLIO 308 19.12.4 RECENT DEVELOPMENT 308 19.13 INVITAE CORPORATION 309 19.13.1 COMPANY PROFILE 309 19.13.2 REVENUE ANALYSIS 309 19.13.3 PRODUCT PORTFOLIO 310 19.13.4 RECENT DEVELOPMENT 310 19.14 NEUSOFT CORPORATION 311 19.14.1 COMPANY SNAPSHOT 311 19.14.2 REVENUE ANALYSIS 311 19.14.3 PRODUCT PORTFOLIO 312 19.14.4 RECENT DEVELOPMENT 312 19.15 NEOGENOMICS LABORATORIES 313 19.15.1 COMPANY SNAPSHOT 313 19.15.2 REVENUE ANALYSIS 313 19.15.3 PRODUCT PORTFOLIO 314 19.15.4 RECENT DEVELOPMENTS 314 19.16 PERKINELMER INC 315 19.16.1 COMPANY PROFILE 315 19.16.2 REVENUE ANALYSIS 315 19.16.3 PRODUCT PORTFOLIO 316 19.16.4 RECENT DEVELOPMENT 316 19.17 QIAGEN 317 19.17.1 COMPANY SNAPSHOT 317 19.17.2 REVENUE ANALYSIS 317 19.17.3 PRODUCT PORTFOLIO 318 19.17.4 RECENT DEVELOPMENT 318 19.18 SYSMEX CORPORATION 319 19.18.1 COMPANY SNAPSHOT 319 19.18.2 REVENUE ANALYSIS 319 19.18.3 PRODUCT PORTFOLIO 320 19.18.4 RECENT DEVELOPMENTS 320 20 QUESTIONNAIRE 321 21 RELATED REPORTS 325